NEW YORK, NY / ACCESSWIRE / February 1, 2023 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
FXLV Shareholders Click Here: https://www.zlk.com/pslra-1/f45-training-lawsuit-submission-form?prid=36132&wire=1
FATE Shareholders Click Here: https://www.zlk.com/pslra-1/fate-therapeutics-class-action-submission-form?prid=36132&wire=1
EYE Shareholders Click Here: https://www.zlk.com/pslra-1/national-vision-class-action-submission-form?prid=36132&wire=1
* ADDITIONAL INFORMATION BELOW *
F45 Training Holdings Inc. (NYSE:FXLV)
This lawsuit is on behalf of all persons and entities that purchased or otherwise acquired the common stock of F45 pursuant and/or traceable to documents issued in connection with the Company's July 16, 2021 initial public offering.
Lead Plaintiff Deadline : February 6, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/f45-training-lawsuit-submission-form?prid=36132&wire=1
According to the filed complaint, 1) F45 Training could not maintain new franchise growth because it was offering more favorable payment terms to multi-unit franchisees; 2) F45 Training's lackluster pace of growth was also accompanied by a massive and unsustainable increase in F45 Training's accounts receivable and a similar, and equally unsustainable, decrease in its cash and cash equivalents; and 3) these practices were not sustainable at the time of the initial public offering, and when F45 Training could no longer sustain this defective business model, its growth rate and revenue plummeted.
Fate Therapeutics, Inc. (NASDAQ:FATE)
FATE Lawsuit on behalf of: investors who purchased April 2, 2020 - January 5, 2023
Lead Plaintiff Deadline : March 22, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/fate-therapeutics-class-action-submission-form?prid=36132&wire=1
According to the filed complaint, during the class period, Fate Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the global collaboration and option agreement for cell-based cancer immunotherapies that the Company entered into with Janssen Biotech, Inc. (the 'Janssen Collaboration Agreement') was less sustainable than Fate had represented to investors; (ii) accordingly, certain the clinical programs, milestone payments, and royalty payments associated with the Janssen Collaboration Agreement could not be relied upon as future revenue sources; (iii) as a result, Fate had overstated the impact of the Janssen Collaboration Agreement's on Fate's long-term clinical and commercial profitability; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
National Vision Holdings, Inc. (NASDAQ:EYE)
This lawsuit is on behalf of all persons who purchased shares of National Vision common stock between May 13, 2021, and May 9, 2022, both dates inclusive.
Lead Plaintiff Deadline : March 28, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/national-vision-class-action-submission-form?prid=36132&wire=1
According to the filed complaint, (a) National Vision was experiencing extraordinary wage and labor pressures as a result of intense competition and disruptions in the labor market due to the COVID-19 pandemic; (b) National Vision had made a significant multi-million dollar investment in wage and compensation payments to its vision care professionals in order to prevent mass defections in the middle of 2021; (c) the enhanced payouts were expected to negatively impact the Company's fourth quarter 2021 costs and profit margins to an extent materially greater than what had been disclosed to investors; (d) as a result of (a)-(c) above, the Company's profitability metrics were expected to deteriorate below not only favorable 2020 results, but also pre-pandemic levels; e) the Company's recruitment and retention efforts had not been successful and there was a substantial undisclosed risk that National Vision would experience staff and optometrist shortages and capacity constraints.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: https://www.accesswire.com/737743/CLASS-ACTION-UPDATE-for-FXLV-FATE-and-EYE-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders